A PHASE 1/2 STUDY OF EG-70 AS AN INTRAVESICAL ADMINISTRATION TO PATIENTS WITH
BCG-UNRESPONSIVE NMIBC AND HIGH-RISK NMIBC PATIENTS WHO ARE BCG NAÏVE
OR RECEIVED INCOMPLETE BCG TREATMENT
- Registry ID
- EG-70-101
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- ENGENE HOLDINGS
- Start date
- 2025-04-24
- Last update
- 2024-02-01
Conditions
- NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)
Related clinical trials
- A PHASE 2, MULTI-ARM, MULTI-COHORT, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF
CRETOSTIMOGENE GRENADENOREPVEC IN PARTICIPANTS WITH HIGH-RISK NON-MUSCLE-INVASIVE
BLADDER CANCER (NMIBC)
- A PHASE 2 OPEN-LABEL RANDOMIZED STUDY OF V940 IN COMBINATION WITH BCG
VERSUS BCG MONOTHERAPY IN PARTICIPANTS WITH HIGH-RISK NON-MUSCLE INVASIVE
BLADDER CANCER (INTERPATH-011)
- A PHASE 3, RANDOMISED, MULTI-CENTRE, OPEN LABEL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC ALONE OR IN COMBINATION WITH CHEMOTHERAPY (GEMCITABINE AND DOCETAXEL) OR IMMUNOTHERAPY (PEMBROLIZUMAB) IN SUBJECTS WITH HIGH-GRADE BACILLUS CALMETTE-GUERIN (BCG) UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)"
- A PHASE 1/2 OPEN-LABEL CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF
INTRAVESICAL SACITUZUMAB TIRUMOTECAN (SAC-TMT, MK-2870) IN PARTICIPANTS
WITH INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)
- A PHASE 3B, RANDOMISED, CONTROLLED TRIAL OF NADOFARAGENE FIRADENOVEC VS. OBSERVATION IN SUBJECTS WITH INTERMEDIATE RISK (IR) NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)
- A PHASE 2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND ANTI-TUMOR ACTIVITY OF INTRAVESICAL INSTILLATION OF TARA-002 IN ADULTS WITH HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER
View on source registry